Embolization of the middle meningeal artery: embolization of the middle meningeal artery with an embolic agent (Microparticles, liquid embolic agents, SwiftPAC coils or others).
Study summary
EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH.
Hypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
\- All patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic.
Exclusion Criteria:
* If informed consent cannot be obtained from the patient or their substitute decision maker.
* Known allergy to liquid embolic agent
Primary outcome measure(s)
Radiographic recurrence — up to 90-days for EMMA Recurrence of CSDH on imaging (CT scan or MRI) of head .
Symptomatic recurrence — up to 90-days from EMMA Symptomatic recurrence attributable to the side of the CSDH on imaging (CT scan or MRI) of head
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.